As of July, 3 The EPS for Nightstar Therapeutics plc (NITE) Expected At $-0.38

June 27, 2018 - By Alice Reed

On July, 3 WallStreet expected Nightstar Therapeutics plc (NASDAQ:NITE)’s earnings report, according to Faxor. The stock increased 0.19% or $0.03 during the last trading session, hitting $16.12.Nightstar Therapeutics plc is after having 0.00% since June 27, 2017. NITE has 62,238 volume or 124.20% up from normal. NITE underperformed by 12.57% the S&P500.

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom.The firm is worth $360.09 million. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.Last it reported negative earnings. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy.

For more Nightstar Therapeutics plc (NASDAQ:NITE) news posted recently go to: 247Wallst.com, Seekingalpha.com, Streetinsider.com, Schaeffersresearch.com or Globenewswire.com. The titles are as follows: “Why Nightstar Is Thursday’s Top Biotech” posted on June 14, 2018, “Nightstar Therapeutics reports Q1 results” on June 06, 2018, “Nightstar Therapeutics plc (NITE) Granted Regenerative Medicine Advanced Therapy Designation from FDA for NSR …” with a publish date: June 14, 2018, “2 Drug Stocks Moving on FDA News” and the last “Nightstar Therapeutics to Present at Jefferies 2018 Global Healthcare Conference” with publication date: May 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.